Mythili Shastry

1.9k total citations · 1 hit paper
38 papers, 1.2k citations indexed

About

Mythili Shastry is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Mythili Shastry has authored 38 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 16 papers in Cancer Research. Recurrent topics in Mythili Shastry's work include Cancer Treatment and Pharmacology (23 papers), HER2/EGFR in Cancer Research (22 papers) and Advanced Breast Cancer Therapies (13 papers). Mythili Shastry is often cited by papers focused on Cancer Treatment and Pharmacology (23 papers), HER2/EGFR in Cancer Research (22 papers) and Advanced Breast Cancer Therapies (13 papers). Mythili Shastry collaborates with scholars based in United States and United Kingdom. Mythili Shastry's co-authors include Erika Hamilton, Sandra M. Swain, Denise A. Yardley, John D. Hainsworth, Howard A. Burris, Saya Jacob, Hope S. Rugo, S. Michelle Shiller, Rongqin Ren and Kent C. Shih and has published in prestigious journals such as Journal of Clinical Oncology, Nature Reviews Drug Discovery and Cancer Research.

In The Last Decade

Mythili Shastry

36 papers receiving 1.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting HER2-positive breast cancer: advances and future directions

2022 583 citations Sandra M. Swain, Mythili Shastry et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mythili Shastry United States	15	706	396	291	285	235	38	1.2k
Yang Luo China	21	989 1.4×	371 0.9×	529 1.8×	236 0.8×	476 2.0×	135	1.5k
Christoph A. Schatz Germany	15	525 0.7×	503 1.3×	173 0.6×	375 1.3×	346 1.5×	47	1.2k
Maria Martinez‐García Spain	18	675 1.0×	386 1.0×	318 1.1×	120 0.4×	389 1.7×	81	1.3k
Dustin A. Deming United States	24	1.0k 1.5×	616 1.6×	455 1.6×	114 0.4×	327 1.4×	157	1.8k
Josep Garcia Switzerland	12	442 0.6×	473 1.2×	374 1.3×	143 0.5×	354 1.5×	33	1.4k
Stephen P. Anthony United States	14	881 1.2×	482 1.2×	603 2.1×	90 0.3×	368 1.6×	53	1.5k
Dana T. Aftab United States	20	882 1.2×	803 2.0×	417 1.4×	112 0.4×	574 2.4×	45	1.8k
Luka Milas United States	19	643 0.9×	489 1.2×	257 0.9×	230 0.8×	376 1.6×	41	1.4k
Arne Scholz Germany	26	995 1.4×	714 1.8×	319 1.1×	412 1.4×	490 2.1×	64	1.9k

Countries citing papers authored by Mythili Shastry

Since Specialization

Citations

This map shows the geographic impact of Mythili Shastry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mythili Shastry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mythili Shastry more than expected).

Fields of papers citing papers by Mythili Shastry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mythili Shastry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mythili Shastry. The network helps show where Mythili Shastry may publish in the future.

Co-authorship network of co-authors of Mythili Shastry

This figure shows the co-authorship network connecting the top 25 collaborators of Mythili Shastry. A scholar is included among the top collaborators of Mythili Shastry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mythili Shastry. Mythili Shastry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Falchook, Gerald S., et al.. (2024). A phase Ib study evaluating the c-MET inhibitor INC280 (capmatinib) in combination with bevacizumab in patients with high-grade glioma. Neuro-Oncology Advances. 7(1). vdae220–vdae220.

Shastry, Mythili & Erika Hamilton. (2023). Novel Estrogen Receptor-Targeted Agents for Breast Cancer. Current Treatment Options in Oncology. 24(7). 821–844. 17 indexed citations

Swain, Sandra M., Mythili Shastry, & Erika Hamilton. (2022). Targeting HER2-positive breast cancer: advances and future directions. Nature Reviews Drug Discovery. 22(2). 101–126. 583 indexed citations breakdown →

Yardley, Denise A., Robyn R. Young, Kerin B. Adelson, et al.. (2021). A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC). Clinical Breast Cancer. 22(3). 269–278. 9 indexed citations

Yardley, Denise A., Robyn R. Young, Kerin B. Adelson, et al.. (2021). Abstract PS11-29: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic triple-negative breast cancer (TNBC). Cancer Research. 81(4_Supplement). PS11–29. 1 indexed citations

Yardley, Denise A., N. W. Peacock, Brooke Daniel, et al.. (2020). Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy. Breast Cancer Research and Treatment. 180(3). 647–655. 5 indexed citations

Yardley, Denise A., William H. Liggett, Mark Mainwaring, et al.. (2019). A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. Clinical Breast Cancer. 20(2). 89–97. 6 indexed citations

Sammons, Sarah, Mythili Shastry, Susan Dent, Carey K. Anders, & Erika Hamilton. (2019). Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2− Breast Cancer. Clinical Breast Cancer. 20(1). 1–11. 21 indexed citations

Hainsworth, John D., Kevin Becker, Tarek Mekhail, et al.. (2019). Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II). Journal of Neuro-Oncology. 144(2). 303–311. 41 indexed citations

10.

Yardley, Denise A., Lowell L. Hart, Patrick J. Ward, et al.. (2018). Cabazitaxel Plus Lapatinib as Therapy for HER2+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study. Clinical Breast Cancer. 18(5). e781–e787. 12 indexed citations

11.

Yardley, Denise A., Dianna Shipley, Patrick J. Ward, et al.. (2018). A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer. Clinical Breast Cancer. 19(1). 1–9. 7 indexed citations

12.

Yardley, DA, et al.. (2016). Abstract P5-14-04: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic breast cancer: Interim analysis. Cancer Research. 76(4_Supplement). P5–14. 4 indexed citations

13.

Shih, Kent C., Sajeel Chowdhary, Alva B. Weir, et al.. (2016). A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. Journal of Neuro-Oncology. 129(2). 281–288. 88 indexed citations

14.

Yardley, DA, P. Chandra, Patrick J. Ward, et al.. (2016). Abstract P1-14-06: A phase II randomized study with eribulin/cyclophosphamide (ErC) and docetaxel/cyclophosphamide (TC) as neoadjuvant therapy in HER2-negative breast cancer- Final analysis of primary endpoint and correlative analysis results. Cancer Research. 76(4_Supplement). P1–14. 1 indexed citations

15.

Yardley, Denise A., Dianna Shipley, N. W. Peacock, et al.. (2015). Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer. Breast Cancer Research and Treatment. 152(3). 557–567. 14 indexed citations

16.

Yardley, Denise A., N. W. Peacock, Mythili Shastry, et al.. (2015). A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score. Breast Cancer Research and Treatment. 154(2). 299–308. 45 indexed citations

17.

Shastry, Mythili & Denise A. Yardley. (2012). Updates in the treatment of basal/triple-negative breast cancer. Current Opinion in Obstetrics & Gynecology. 25(1). 40–48. 38 indexed citations

18.

Yardley, DA, Carolyn B. Hendricks, Charles Webb, et al.. (2012). Abstract P1-14-14: Neoadjuvant Sunitinib (S) Administered with Weekly Paclitaxel (P)/Carboplatin(C) in Patients (Pts) with Locally Advanced Triple-Negative Breast Cancer (TNBC): Preliminary Results from a Phase I/II Trial of the Sarah Cannon Research Institute.. Cancer Research. 72(24_Supplement). P1–14. 1 indexed citations

19.

Yardley, Denise A., Eric Raefsky, Dana S. Thompson, et al.. (2011). Phase II Study of Neoadjuvant Weekly nab-Paclitaxel and Carboplatin, With Bevacizumab and Trastuzumab, As Treatment For Women With Locally Advanced HER2+ Breast Cancer. Clinical Breast Cancer. 11(5). 297–305. 42 indexed citations

20.

Yardley, Denise A., Davey B. Daniel, Mark Mainwaring, et al.. (2010). A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer. Cancer Investigation. 28(8). 865–871. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact